CAPABILITIES OF MODERN PHARMACOTHERAPY FOR CORONARY HEART DISEASE WITH EXERCISE-INDUCED STABLE ANGINA
Issue:
7
Year:
2016
The time course of changes in the physical and psychological components of quality of life (QL) was analyzed in patients with coronary heart disease and functional class II-III angina pectoris during therapy with nicorandil and isosorbide dinitrate. The QL indicators were improved to a greater extent marked when nicorandil was used long.
Keywords:
quality of life
coronary heart disease
exercise-induced angina
pharmacotherapy
nicorandil
References:
- Afanas'eva E.V. Otsenka kachestva zhizni, svjazannogo so zdorov'em // Kachestvennaja klinicheskaja praktika. – 2010; 1: 56–8.
- Novik A.A., Ionova T.I. Rukovodstvo po issledovaniju kachestva zhizni v meditsine. Pod red. akad. RAMN Ju.L. Shevchenko / SPb, ID Neva; M.; Olma- Press Zvezdnyj mir, 2007; 320 s.
- Kind P., Williams A. Measuring success in health care – the time has come to do it properly // Health Policy Matter. – 2004; Issue 9: 1–8.
- Krom I.L., Erugina M.V., Sazanova G.Ju. Otsenka meditsinskoj pomoschi v kontekste kachestva zhizni bol'nyh ishemicheskoj bolezn'ju serdtsa // Fundamental'nye issledovanija. – 2015; 1–6: 1174–7.
- Shal'nova S.A., Konradi A.O., Karpov Ju.A. i dr. Analiz smertnosti ot serdechno-sosudistyh zabolevanij v 12 regionah Rossijskoj Federatsii, uchastvujuschih v issledovanii «Epidemiologija serdechno-sosudistyh zabolevanij v razlichnyh regionah Rossii» // Ros. kardiol. zhurn. – 2012; 5: 6–11.
- Kardiovaskuljarnaja profilaktika. Natsional'nye rekomendatsii. VNOK // Kardiovask. ter. i prof. – 2011; 6 (pril. 2): 57.
- Egorov V.A., Shilova E.V., Martsevich S.Ju. Vybor terapii nitratami u bol'nyh stabil'noj stenokardiej naprjazhenija: sravnitel'noe issledovanie obychnyh tabletok izosorbida dinitrata i razlichnyh lekarstvennyh form izosorbida-5-mononitrata // Rats. farmakoter. v kardiol. – 2008; 2: 19–22.
- Zhiljaev E.V. Nitraty v lechenii stabil'noj stenokardii: novye gorizonty // Sonsilium Medicum. – 2010; 1: 14–8.
- Roland E. Safety profile of an anti-anginal agent with potassium channel opening activity: an overview // Eur. Heart J. – 1993; 14 (Suppl. B): 40–7.
- Shimbo D., Grahame-Clarke C., Miyake Y. et al. The association between endothelial dysfunction and cardiovascular outcomes in a population-based multiethnic cohort // Atherosclerosis. – 2007; 192 (1): 197–203.
- Kitakaze M., Asakura M., Kim J. et al. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials // Lancet. – 2007; 370: 1483–93.
- Sizova Zh.M., Zaharova V.L., Shamieva E.S. i dr. Vozmozhnosti kordinika v korrektsii koronarnogo rezerva i endotelial'noj disfunktsii u bol'nyh ishemicheskoj bolezn'ju serdtsa // Serdtse. – 2013; 2 (70, t. 12): 75–81.
- Sizova Zh.M. Kozlova N.V., Zaharova V.L. i dr. Sravnitel'naja otsenka vlijanija izosorbida dinitrata, izosorbida-5-mononitrata i nikorandila na chastotu pristupov stenokardii i vazoregulirujuschuju funktsiju endotelija u bol'nyh ishemicheskoj bolezn'ju serdtsa // Kardiologija. – 2015; 2: 10–5.
- Montalescot G., Sechtem U., Achenbach S. et al. 2013 ESC guidelines on the management of stable coronary artery disease: The Task Force of the European Society of Cardiology // Eur. Heart J. – 2013; 34 (38): 2949–3003.
- Kinoshita M., Sakai K. Pharmacology and Therapeutic Effects of Nicorandil // Cardiovasc. Drugs and Therapy. – 1990; 4: 1075–88.
- Meany T., Richardson P., Camm A. et al. Exercise capacity after single and twice-daily doses of nicorandil in chronic stable angina pectoris // Am. J. Cardiol. – 1989; 63: 66–70.
- Bulahova E.Ju., Korennova O.Ju., Kondrasheva M.N. i dr. Klinicheskie preimuschestva terapii nikorandilom v sravnenii s izosorbid-5- mononitratom u bol'nyh IBS // Serdtse. – 2013; 2 (70, t. 12): 83–7